Introduction
============

Next-generation sequencing technologies allow for sequencing of the exome and genome at a rapid rate, generating a large amount of genomic data. In 2012, the American College of Medical Genetics and Genomics (ACMG) published a statement regarding the clinical application of genomic sequencing stating that "The ACMG recognizes that genomic sequencing approaches can be of great value in the clinical evaluation of individuals with suspected germline genetic disorders... results will provide an explanation for a patient\'s phenotype by identifying a mutation in a gene known to be associated with the patient\'s clinical condition or in a gene that is highly likely to be causative given current knowledge"^[@bib1]^ (**Supplementary Table S1** online). For each exome sequenced, there are thousands of variants identified unrelated to the disease of interest. Although the vast majority of these alterations are likely benign polymorphisms or within clinically novel genes whose function remains largely obscure, a small number (\<5) of well-described disease-association mutations are typically detected (unpublished data). For example, nonbiased massively parallel sequencing-based carrier-screening assays show that every individual carries an average of 2.8 mutations among genes known to cause severe pediatric disease in the recessive form.^[@bib2]^ Among 37 well-described cancer predisposition genes, \~1% of individuals manifest a likely pathogenic cancer predisposition gene alteration.^[@bib3]^ Although secondary to the referral indication for exome sequencing, these variants may also have important clinical and medical consequences for the patient including presymptomatic screening, family reproductive planning, carrier testing, prenatal diagnosis, and prophylactic intervention.

Currently, several groups describe the ethical obligation to return secondary findings (SFs) in the research setting; however, there remains substantial controversy and no standard accepted method for reporting.^[@bib4],[@bib5],[@bib6],[@bib7],[@bib8],[@bib9],[@bib10],[@bib11],[@bib12],[@bib13],[@bib14],[@bib15],[@bib16],[@bib17],[@bib18],[@bib19],[@bib20],[@bib21],[@bib22]^ In fact, the program director of the National Human Genome Research Institute\'s Ethical, Legal and Social Implications Research Program likened the topic to "arguably the most pressing issue in genetics today."^[@bib23]^ The debated issue within genomic research has been whether to follow the traditional researcher--participant model, where participants receive no feedback even when clinically urgent and actionable information is discovered or to go against convention and provide patients with the option to consent for the disclosure of SFs.^[@bib4],[@bib6],[@bib8],[@bib15],[@bib16],[@bib17],[@bib19],[@bib21],[@bib24],[@bib25],[@bib26],[@bib27]^ One method for disclosure involves the use of a structured model to clinically analyze and categorize relevant secondary results through binning based on the degree of clinical utility and clinical validity.^[@bib10],[@bib28]^ The ACMG recommends that "laboratories and clinics utilizing whole-genome sequencing/whole-exome sequencing should have clear policies in place related to disclosure of SFs. Patients should be informed of those policies and the types of SFs that will be reported back to them and under what circumstances. Patients should be given the option of not receiving certain SFs."^[@bib1]^ It has been questioned whether clinicians may have a legal obligation to release particular SFs; however, to date, there have been no legal cases related to clinical genomic testing.^[@bib15]^ In a recent paper, the ACMG provided recommendations for the return of SFs, which involves the return of variants identified from a provided list of 56 genes without regard for the preference of the patient for these findings.^[@bib29]^ Despite the vast and heated opinions of researchers, clinicians, and committees on the subject of SFs, few studies document the preferences of patients/research participants. Among the relatively few studies which do exist, participants in research studies express a desire for the option to receive results and disclosure decisions depend on a number of factors including the type, conclusiveness, and nature of the results.^[@bib24],[@bib30],[@bib31],[@bib32]^ However, participants in research cohorts are generally healthy or facing non--life-threatening disease (e.g., refs. ^[@bib3],[@bib30],[@bib31]^) and preferences for SFs may differ as compared with those of patients undergoing diagnostic exome sequencing (DES), who are generally affected with chronic and/or life-threatening illnesses.

Given the recent availability of DES, there is a limited knowledge regarding the patient preferences for receiving SFs in the clinical setting. On the basis of the unprecedented experience of a large reference laboratory providing clinical exome sequencing (Ambry Genetics, Aliso Viejo, CA), we provide an analysis of SFs reporting consent among the first 200 patients undergoing diagnostic whole-exome testing.

Materials and Methods
=====================

DNA from 200 patient families sent to Ambry Genetics was extracted from peripheral blood samples and, in rare cases, from processed DNA. Samples were prepared using the SureSelect Target Enrichment System (v2) (Agilent Technologies, Santa Clara, CA) and sequenced using paired-end, 100-cycle chemistry on the Illumina HiSeq 2000 (Illumina, San Diego, CA). A SFs reporting strategy was constructed based on recommendations regarding testing in minors from various professional organizations^[@bib24],[@bib33],[@bib34],[@bib35]^ with which the majority of clinical genetics professionals agree,^[@bib36]^ upon consultation with medical ethicists (H. Greely and M. Cho, personal communication), and was subsequently supported by the ACMG policy statement regarding the clinical application of genomic sequencing^[@bib1]^ (**Supplementary Table S1 online**). Our laboratory requires genetic counseling and DES consenting to aid in informing patients of the complexity of exome sequencing and to allow them the option to consent to or decline SFs disclosure (<http://ambrygen.com/requirements>).

A parent or legal guardian (referred to collectively herein as "guardians") completes the consent form for patients younger than the age of 18 years. Given that the impact and significance of SFs differs widely from that of primary results, patients are informed that SFs are reported separately from the primary exome report. The consent also details that reported SFs include only medically reviewed and previously defined mutations in characterized genes; variants of uncertain significance are not reported. At the time of consent, these SFs included four categories: (i) category A: carrier status of recessive disorders, (ii) category B: predisposition to later-onset disease, (iii) category C: predisposition to increased cancer risk, and (iv) category D: early-onset disease. Within the consent form, patients were provided with the option to receive a SFs report for each of the four categories. Adults (older than 18 years of age) chose among all four categories, whereas minors (younger than 18 years of age) chose whether to receive a category D result. A complete list of the genes and diseases from each of the four categories is available online (<http://ambrygen.com/sites/default/files/pdfs/forms/most_updated/Incidental%20Findings_051313.pdf>). The consent form contains example scenarios within each of the four categories, provided for the purpose of aiding, but not to take the place of, genetic counseling.

Patient demographics (age, diagnosis, and gender) and SFs disclosure decisions were collected from consent forms supplied to the laboratory with the requisition form and the biospecimens. Patient identifiers were removed. Retrospective data analysis of anonymized data exempted the study from the review of institutional review board. Data curation included the primary exome test option ordered, patient age, diagnosis and/or clinical description, and SFs disclosure elections among the four described categories. Statistical analyses were computed by χ^2^ goodness-of-fit tests and Fisher\'s exact probability.

Results
=======

The 200 probands were predominantly from the United States and Canada, and 98% (195/200) were referred by a geneticist/genetic counselor. The five cases which did not involve a geneticist or genetic counselor were ordered for probands younger than the age of 18 years. Moreover, 81% (*n* = 162) of the referred probands were children (younger than 18 years of age) (**[Table 1](#tbl1){ref-type="table"}**). The average ages among children and adults were 5 and 38 years, respectively, with mean ages of 4 and 33 years, respectively. All patients were affected with a genetic disorder. The most common referral indications were neurological disease, multiple congenital anomalies, musculoskeletal anomalies, and metabolic disease (data not shown). Among the referrals within the adult cohort, common referrals also included cancer predisposition, immunologic disease, and nonsyndromic intellectual disability; metabolic disease was less common.

The majority of patients (187/200; 93.5%) consented to SFs reporting for one or more available categories (**[Table 2](#tbl2){ref-type="table"}**). Guardians of 7 of 162 children (4%) did not consent to SFs reporting of category D, the one category available to them, whereas 16% (6/38) of adults did not consent to SFs reporting of one or more category, making adults significantly less likely to consent to SFs reporting (16 vs. 4%, respectively; *P* \< 0.0001). Of the six adults who chose to blind one or more SFs, options for blinding were scattered between the four different categories, and only one chose to blind all four categories. Specifically, 8% (3/38) did not consent to SFs reporting of recessive disease carrier status; 11% (4/38) cancer predisposition, 8% (3/38) adult-onset disease predisposition, and 8% (3/38) early-onset disease. Among all patients regardless of age, 5% (10/200) did not consent to SFs reporting of early-onset disease. Lack of consent to SFs reporting among each category was evenly distributed between among six adult patients (**[Table 3](#tbl3){ref-type="table"}**). Of note, only one adult did not consent to SFs reporting of all four categories. Overall, patients were significantly more likely to consent to SFs reporting than not (*P* \< 0.0001).

Discussion
==========

Overwhelmingly, patients undergoing DES consent to disclosure of all available SFs. The health status among the cohort of subjects herein emerges as a significant variable. Individuals pursuing DES may be more active in seeking medical information and therefore more receptive to obtaining SFs information than healthy individuals. Each of these factors may decrease fear regarding future disease risk while heightening desire to both find any possible contribution to a possible diagnosis as well as be prepared for additional findings which may further burden current health. In general, patients undergoing DES represent an extreme end of the health spectrum which introduces a substantial bias regarding threshold for disease risk acceptance, not likely generalizable to the general population.

Likelihood to consent is significantly greater among DES patients younger than the age of 18 years, perhaps further implicating health status as a factor influencing the impetus to opt for disclosure. The majority of patients within the child cohort were affected with complex diseases including severe cognitive impairment and a truncated life expectancy and represent the most severe end of the phenotypic spectrum. Most often, these children are faced with life-threatening illnesses with truncated life expectancies, have spent years or even decades in search of a diagnosis, and may have multiple affected family members. The adult DES patients had milder disease manifestations and were less likely affected with life-threatening diseases or severe cognitive impairment. However, the observed difference between preferences among adults and children might also reflect a difference between information parents would like to learn about their children, versus information that adult patients would like to learn about themselves.

No apparent sex or age bias emerged when comparing consenting versus nonconsenting adult DES patients. Of note, among the six adults opting for blinding of SFs, there is no trend toward blinding of any specific subcategory, possibly indicating an intricate and complicated decision-making process, more closely matching that of healthy participants in research studies where disclosure decisions depend on a number of factors, likely based on personal life experiences.^[@bib24],[@bib30],[@bib31],[@bib32]^

It is curious that 15% of guardians opted for secondary reporting for predictive genetic test results including predisposition and carrier status for their children, despite the unavailability of these results to minors. It is possible that this result was confounded by practicalities such as the quality of genetic counseling, time constraints in busy clinics, or limitations in the understanding of the implications of these SFs. Although this may have been a mistake or oversight by the clinician or guardian at the time of consent, the choice for these findings draws attention to the issue of genetic testing in minors, which has been debated for years (e.g., refs. ^[@bib24],[@bib32],[@bib33],[@bib34],[@bib35],[@bib36],[@bib37],[@bib38],[@bib39]^). Notably, the recent ACMG guidelines for SFs reporting recommend the disclosure of several adult-onset predisposition disease genes.^[@bib29]^ In general, testing in minors has been discouraged when the benefits of the test will not accrue until adulthood such as with late-onset diseases or conditions without medical management or clinical significance.^[@bib4]^ Genetic testing in minors is only recommended when the current potential benefits outweigh the harms.^[@bib4],[@bib24]^ Those opposed to predictive testing believe that it may take away their autonomy, hinder their confidentiality, and believe the possibility of harm to be greater than the benefits of disclosing results to the parent/guardian.^[@bib24],[@bib38]^ Those in favor of testing describe avoiding paternalism, increasing patient autonomy, and reducing anxiety among other psychological benefits.^[@bib30],[@bib38]^ Notably, cognitive impairment has been discussed among the limited circumstances in which predictive genetic testing in minors may be appropriate.^[@bib39]^ Studies have shown few patients have regretted receiving results for predictive genetic testing.^[@bib36],[@bib37]^ Overall, a recent chronological review of the ethical arguments for predictive genetic testing in minors describes a gradual shift toward ethical arguments in favor of testing.^[@bib38]^ Other studies cite this same trend.^[@bib24]^

A potential source of variation in our data is in the level and depth of counseling/consenting provided to families referred for exome sequencing from clinicians with inherently different counseling styles, from clinics with varying levels of patient loads and processes. The majority of cases analyzed in this study involved a clinical geneticist or genetic counselor in the consent process, highlighting the quality of counseling. However, this potential variability in the delivery of counseling and consent did not appear to influence family decisions given that families overwhelmingly opted for SFs disclosure.

Overall, the data herein provide, for the first time, a preliminary study of the SFs report preferences among a small cohort of families undergoing DES in a clinical setting including 161 severely affected children and 39 somewhat less severely affected adults. Larger cohort studies including direct patient interviews to further define the implications and to address the impact of this strategy of SFs results return are warranted.
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